Inc. increased its stake in shares of Shire PLC by 3.1% in the first quarter. The SI to Enzymotec Limited Ord's float is 0.58%. The average volume stands around 1.34 million shares. It is down 13.94% since August 22, 2016 and is uptrending.
Shire PLC has a PE ratio of 48.50 with a one year low of 3,603.50GBX and a one year high of 5,377.00GBX Shire PLC's market capitalization is presently 0 GBX. Shire PLC has a 1-year low of $139.36 and a 1-year high of $209.22. If the $131.13 price target is reached, the company will be worth $2.98 billion less. The average numbers of shares are traded in a security per day, during the recent 3-month period. Sector Gamma As acquired 62,500 shares as Shire Plc (SHPG)'s stock rose 4.45%. It has underperformed by 16.70% the S&P500. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. Therefore 43% are positive. Rubicon Project had 19 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Enzymotec Ltd (NASDAQ:ENZY) has "Hold" rating given on Thursday, June 15 by Jefferies. RBC Capital Markets maintained the stock with "Outperform" rating in Tuesday, July 25 report. The rating was upgraded by Societe Generale to "Buy" on Monday, September 26. The stock has "Overweight" rating by Barclays Capital on Friday, June 9. The company has market cap of $135.51 million.
The company is trading down by -3.23 percent from yesterday's close. The Firm operates primarily through its wholly owned bank subsidiary, MidSouth Bank, N.A. It now has negative earnings. The Firm operates in two divisions: Nutrition segment and VAYA Pharma segment. M&R Capital Management Inc sold 3,720 shares as Shire Plc Sponsored Adr (SHPG)'s stock rose 4.45%. Therefore 83% are positive. Jefferies Group LLC reaffirmed a "buy" rating and issued a $216.00 price target (down previously from $239.00) on shares of Shire PLC in a report on Friday, June 9th. J P Morgan Chase & Co restated an "overweight" rating and issued a GBX 6,000 ($77.89) target price on shares of Shire PLC in a report on Friday, May 19th. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company's stock valued at $100,000 after buying an additional 92 shares during the last quarter. Shire PLC (ADR) (NASDAQ:SHPG) has risen 4.69% since August 22, 2016 and is uptrending. The stock of Shire PLC (ADR) (NASDAQ:SHPG) earned "Hold" rating by HSBC on Thursday, July 6.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Thursday, August 3rd.
The firm also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. The rating was upgraded by HSBC to "Hold" on Wednesday, September 30. As per Tuesday, July 11, the company rating was maintained by Cantor Fitzgerald. Northland Capital initiated the shares of SHPG in report on Wednesday, October 14 with "Outperform" rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.